Recent Updates
Recently added Catalysts

Ketoconazole + GW642444M

Phase 1

Pulmonary Disease, Chronic Obstructive | Small molecule | Other |GSK plc|Last Updated: Jul 18, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00866515Drug Interaction Study to Investigate Co-administration of GW642444M With KetoconazolePHASE1 COMPLETED 20Dec 22, 2008Mar 27, 2009Jul 18, 20171 Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Supine heart rate and blood potassium levels
Day 5
Secondary Endpoints
Plasma GW642444M concentrations
Day 5
Reported Adverse Events
treatment periods
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ActiveEXPERIMENTALKetoconazole 400mg OD days 1-6
PlaceboPLACEBO_COMPARATORPlacebo OD for 1 to 6 days
Interventions
NameTypeDescription
Ketoconazole + GW642444MDRUGKetoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
Placebo + GW642444MDRUGPlacebo to match D1-6 + GW642444M 25ug single dose on D5
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range ...

Countries:Australia
Unlock Eligibility Criteria